Literature DB >> 19297492

Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys.

Sylvain Baize1, Philippe Marianneau, Philippe Loth, Stéphanie Reynard, Alexandra Journeaux, Michèle Chevallier, Noël Tordo, Vincent Deubel, Hugues Contamin.   

Abstract

Lassa virus causes a hemorrhagic fever endemic in West Africa. The pathogenesis and the immune responses associated with the disease are poorly understood, and no vaccine is available. We followed virological, pathological, and immunological markers associated with fatal and nonfatal Lassa virus infection of cynomolgus monkeys. The clinical picture was characterized by fever, weight loss, depression, and acute respiratory syndrome. Transient thrombocytopenia and lymphopenia, lymphadenopathy, splenomegaly, infiltration of mononuclear cells, and alterations of the liver, lungs, and endothelia were observed. Survivors exhibited fewer lesions and a lower viral load than nonsurvivors. Although all animals developed strong humoral responses, antibodies appeared more rapidly in survivors and were directed against GP(1), GP(2), and NP. Type I interferons were detected early after infection in survivors but only during the terminal stages in fatalities. The mRNAs for CXCL10 (IP-10) and CXCL11 (I-TAC) were abundant in peripheral blood mononuclear cells and lymph nodes from infected animals, but plasma interleukin-6 was detected only in fatalities. In survivors, high activated-monocyte counts were followed by a rise in the total number of circulating monocytes. Activated T lymphocytes circulated in survivors, whereas T-cell activation was low and delayed in fatalities. In vitro stimulation with inactivated Lassa virus induced activation of T lymphocytes from all infected monkeys, but only lymphocytes from survivors proliferated. Thus, early and strong immune responses and control of viral replication were associated with recovery, whereas fatal infection was characterized by major alterations of the blood formula and, in organs, weak immune responses and uncontrolled viral replication.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19297492      PMCID: PMC2681932          DOI: 10.1128/JVI.01948-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  68 in total

1.  RING finger Z protein of lymphocytic choriomeningitis virus (LCMV) inhibits transcription and RNA replication of an LCMV S-segment minigenome.

Authors:  T I Cornu; J C de la Torre
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

Review 2.  Lassa fever.

Authors:  J B McCormick; S P Fisher-Hoch
Journal:  Curr Top Microbiol Immunol       Date:  2002       Impact factor: 4.291

3.  Monitoring of clinical and laboratory data in two cases of imported Lassa fever.

Authors:  Herbert Schmitz; Bernhard Köhler; Thomas Laue; Christian Drosten; Peter J Veldkamp; Stephan Günther; Petra Emmerich; Hans P Geisen; Klaus Fleischer; Matthias F C Beersma; Achim Hoerauf
Journal:  Microbes Infect       Date:  2002-01       Impact factor: 2.700

4.  In vivo hematologic effects of recombinant interleukin-6 on hematopoiesis and circulating numbers of RBCs and WBCs.

Authors:  T R Ulich; J del Castillo; K Z Guo
Journal:  Blood       Date:  1989-01       Impact factor: 22.113

5.  Host cell-dependent homologous interference in lymphocytic choriomeningitis virus infection.

Authors:  M Bruns; A Gessner; H Lother; F Lehmann-Grube
Journal:  Virology       Date:  1988-09       Impact factor: 3.616

6.  Clinical virology of Lassa fever in hospitalized patients.

Authors:  K M Johnson; J B McCormick; P A Webb; E S Smith; L H Elliott; I J King
Journal:  J Infect Dis       Date:  1987-03       Impact factor: 5.226

7.  Physiological and immunologic disturbances associated with shock in a primate model of Lassa fever.

Authors:  S P Fisher-Hoch; S W Mitchell; D R Sasso; J V Lange; R Ramsey; J B McCormick
Journal:  J Infect Dis       Date:  1987-03       Impact factor: 5.226

8.  Attrition of bystander CD8 T cells during virus-induced T-cell and interferon responses.

Authors:  J M McNally; C C Zarozinski; M Y Lin; M A Brehm; H D Chen; R M Welsh
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

9.  Hemorrhagic fever occurs after intravenous, but not after intragastric, inoculation of rhesus macaques with lymphocytic choriomeningitis virus.

Authors:  Igor S Lukashevich; Mahmoud Djavani; Juan D Rodas; Juan C Zapata; Amy Usborne; Carol Emerson; Jacque Mitchen; Peter B Jahrling; Maria S Salvato
Journal:  J Med Virol       Date:  2002-06       Impact factor: 2.327

10.  Hematologic dysfunction in Lassa fever.

Authors:  S Fisher-Hoch; J B McCormick; D Sasso; R B Craven
Journal:  J Med Virol       Date:  1988-10       Impact factor: 2.327

View more
  96 in total

1.  Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus.

Authors:  Delphine Pannetier; Stéphanie Reynard; Marion Russier; Alexandra Journeaux; Noël Tordo; Vincent Deubel; Sylvain Baize
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Virology: One protein, many functions.

Authors:  Félix A Rey
Journal:  Nature       Date:  2010-12-09       Impact factor: 49.962

3.  Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus.

Authors:  Kristian G Andersen; B Jesse Shapiro; Christian B Matranga; Rachel Sealfon; Aaron E Lin; Lina M Moses; Onikepe A Folarin; Augustine Goba; Ikponmwonsa Odia; Philomena E Ehiane; Mambu Momoh; Eleina M England; Sarah Winnicki; Luis M Branco; Stephen K Gire; Eric Phelan; Ridhi Tariyal; Ryan Tewhey; Omowunmi Omoniwa; Mohammed Fullah; Richard Fonnie; Mbalu Fonnie; Lansana Kanneh; Simbirie Jalloh; Michael Gbakie; Sidiki Saffa; Kandeh Karbo; Adrianne D Gladden; James Qu; Matthew Stremlau; Mahan Nekoui; Hilary K Finucane; Shervin Tabrizi; Joseph J Vitti; Bruce Birren; Michael Fitzgerald; Caryn McCowan; Andrea Ireland; Aaron M Berlin; James Bochicchio; Barbara Tazon-Vega; Niall J Lennon; Elizabeth M Ryan; Zach Bjornson; Danny A Milner; Amanda K Lukens; Nisha Broodie; Megan Rowland; Megan Heinrich; Marjan Akdag; John S Schieffelin; Danielle Levy; Henry Akpan; Daniel G Bausch; Kathleen Rubins; Joseph B McCormick; Eric S Lander; Stephan Günther; Lisa Hensley; Sylvanus Okogbenin; Stephen F Schaffner; Peter O Okokhere; S Humarr Khan; Donald S Grant; George O Akpede; Danny A Asogun; Andreas Gnirke; Joshua Z Levin; Christian T Happi; Robert F Garry; Pardis C Sabeti
Journal:  Cell       Date:  2015-08-13       Impact factor: 41.582

4.  Pathogenic Old World arenaviruses inhibit TLR2/Mal-dependent proinflammatory cytokines in vitro.

Authors:  Melissa W Hayes; Ricardo Carrion; Jerritt Nunneley; Andrei E Medvedev; Maria S Salvato; Igor S Lukashevich
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

5.  Lassa virus nucleoprotein mutants generated by reverse genetics induce a robust type I interferon response in human dendritic cells and macrophages.

Authors:  Xavier Carnec; Sylvain Baize; Stéphanie Reynard; Laure Diancourt; Valérie Caro; Noel Tordo; Michèle Bouloy
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

6.  Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3' to 5' exonuclease activity essential for immune suppression.

Authors:  Kathryn M Hastie; Christopher R Kimberlin; Michelle A Zandonatti; Ian J MacRae; Erica Ollmann Saphire
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-24       Impact factor: 11.205

7.  Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man.

Authors:  Juan C Zapata; Maria S Salvato
Journal:  Future Virol       Date:  2015-03-13       Impact factor: 1.831

8.  A Case of Human Lassa Virus Infection With Robust Acute T-Cell Activation and Long-Term Virus-Specific T-Cell Responses.

Authors:  Anita K McElroy; Rama S Akondy; Jessica R Harmon; Ali H Ellebedy; Deborah Cannon; John D Klena; John Sidney; Alessandro Sette; Aneesh K Mehta; Colleen S Kraft; Marshall G Lyon; Jay B Varkey; Bruce S Ribner; Stuart T Nichol; Christina F Spiropoulou
Journal:  J Infect Dis       Date:  2017-06-15       Impact factor: 5.226

Review 9.  The search for animal models for Lassa fever vaccine development.

Authors:  Igor S Lukashevich
Journal:  Expert Rev Vaccines       Date:  2013-01       Impact factor: 5.217

10.  Vaccine Platforms to Control Arenaviral Hemorrhagic Fevers.

Authors:  Ricardo Carrion; Peter Bredenbeek; Xiaohong Jiang; Irina Tretyakova; Peter Pushko; Igor S Lukashevich
Journal:  J Vaccines Vaccin       Date:  2012-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.